Cannell & Spears LLC Sells 27,102 Shares of Novo Nordisk A/S $NVO

Cannell & Spears LLC reduced its position in Novo Nordisk A/S (NYSE:NVO) by 69.4% during the third quarter, Holdings Channel.com reports. The institutional investor owned 11,947 shares of the company’s stock after selling 27,102 shares during the period. Cannell & Spears LLC’s holdings in Novo Nordisk A/S were worth $663,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in NVO. True Wealth Design LLC increased its stake in Novo Nordisk A/S by 209.8% in the 3rd quarter. True Wealth Design LLC now owns 443 shares of the company’s stock worth $25,000 after acquiring an additional 300 shares during the last quarter. Guerra Advisors Inc purchased a new stake in shares of Novo Nordisk A/S during the 3rd quarter worth approximately $25,000. Strengthening Families & Communities LLC bought a new position in shares of Novo Nordisk A/S during the 3rd quarter valued at approximately $30,000. Allianz SE grew its holdings in shares of Novo Nordisk A/S by 70.0% in the third quarter. Allianz SE now owns 578 shares of the company’s stock valued at $32,000 after purchasing an additional 238 shares in the last quarter. Finally, Financial Life Planners purchased a new position in shares of Novo Nordisk A/S in the third quarter valued at $33,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 0.1%

Shares of NVO opened at $37.99 on Monday. The company’s fifty day simple moving average is $50.14 and its 200-day simple moving average is $51.73. The company has a market cap of $169.61 billion, a P/E ratio of 10.95 and a beta of 0.74. The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61. Novo Nordisk A/S has a twelve month low of $35.85 and a twelve month high of $82.57.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, topping analysts’ consensus estimates of $0.90 by $0.11. The firm had revenue of $12.43 billion during the quarter, compared to analysts’ expectations of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. As a group, analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Dividend Announcement

The firm also recently announced a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be given a dividend of $1.2751 per share. This represents a dividend yield of 541.0%. The ex-dividend date is Monday, March 30th. Novo Nordisk A/S’s payout ratio is 23.63%.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo’s deal with telehealth/retail player Hims & Hers could broaden channels for GLP‑1 distribution and shift competitive dynamics in the obesity market; Hims shares have surged on the tie-up. Hims shares set for best week on record after new Novo Nordisk deal
• Positive Sentiment: Novo’s partnership with the WHO Foundation to support cardio‑renal‑metabolic programs expands its public‑health footprint and may support long‑term access and reputation in emerging markets. Novo Nordisk WHO Partnership Links Global Health Push With Valuation Story
• Neutral Sentiment: Zacks moved NVO from “strong sell” to “hold,” which slightly reduces near‑term sell‑side pressure but is not a bullish upgrade. Zacks.com
• Neutral Sentiment: Broader health‑care weakness today (NYSE Health Care Index decline) is adding to headline pressure across large pharma names, including NVO. Sector Update: Health Care Stocks Retreat Late Afternoon
• Negative Sentiment: The FDA issued a warning to Novo Nordisk about unreported semaglutide adverse events — the clearest near‑term catalyst for the share decline as it raises risks of inspections, disclosures, labeling changes, prescribing impacts and regulatory enforcement. FDA issues warning to Novo Nordisk on unreported semaglutide safety events
• Negative Sentiment: An investor class‑action/investigation notice (Pomerantz) has been announced, increasing legal risk and potential future claims tied to the disclosure of safety events. Pomerantz investor alert
• Negative Sentiment: Analyst downgrades and negative press—plus reporting that Novo Holdings’ assets shrank after the stock slump—are reinforcing selling momentum and investor concern about valuation and control‑group exposure. Novo Nordisk stock slump hits value of controlling shareholder

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. Citigroup initiated coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 27th. They set a “neutral” rating on the stock. Morgan Stanley raised shares of Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 price objective for the company in a research note on Tuesday, March 3rd. Jefferies Financial Group upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a report on Thursday, February 12th. HSBC restated a “hold” rating and set a $54.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, December 10th. Finally, Weiss Ratings raised shares of Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, February 5th. Four investment analysts have rated the stock with a Buy rating and nineteen have given a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $49.93.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.